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Introduction

S . S . KETY
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts
This symposium will be concerned with an important enzyme that was isolated from the liver of rabbits nearly fifty years ago. Its relevance to psychiatry was recognized thirty years later by a serendipitous discovery-undesirable behavioural side-effects in a drug that was useful in the treatment of tuberculosis. Monoamine oxidase has an interesting history, and a history that includes many of the most important names in biochemistry in the past and present generations. I am indebted to Dr Blaschko for the details of this history, which is well outlined in his paper in Pharmacological Reviews (1952) .
We can trace the history of amine oxidases back to Schmiedeberg, who in 1877 showed that benzylamine was excreted by the dog as hippuric acid, from which he recognized that there was a necessary step in that conversion representing an oxidaion of benzylamine and a deamination to benzoic acid.
In 1883 Minkowski demonstrated in vitro the conversion of benzylamine to benzoic acid. In 1910 Ewins and Laidlaw perfused the liver of the cat and the rabbit with tyramine, which they found to be converted top-hydroxyphenylacetic acid. They also found that tryptamine was oxidized to indoleacetic acid. They made the interesting observation that tyramine could be oxidatively deaminated on perfusion through muscle, but they pointed out that it is only in muscles with a rich sympathetic nerve supply that this conversion takes place. Muscles that were poor in sympathetic nerve endings would not make this conversion.
The characterization of the enzyme responsible for this conversion waited until 1928, when Mary Hare, then 26 years old and a postgraduate student at Newnham College in Cambridge, described a new enzyme system in the liver-tyramine oxidase. In the same year (1928) in which she won her doctorate she also married another biochemist in Cambridge who had come from the United States, Frederick Bernheim. With him she returned to the States, first to Johns Hopkins and then to join the faculty of the new school of medicine at Duke University. Since that time, Dr Bernheim has been very active, both in biochemistry and in many other pursuits.
In that classic paper (Hare 1928) she showed that the oxidation of tyramine by liver homogenates and particulate fractions of the liver was not inhibited by cyanide and therefore was an exception to Warburg's dictum that all oxidation in cells is dependent upon iron. From that she concluded that this oxidation was not produced by tyrosinase, which is blocked by cyanide, and she concluded that she was working with a new and undescribed enzyme. Although she found that her enzyme preparation did not act on catecholamines, in 1937 Dr Blaschko and his co-workers were able to demonstrate this important action, after excluding the autoxidation of adrenaline in aqueous solution. It was at that time that the concept of an amine oxidase with generalized oxidatively deaminating properties was developed. Zeller (1938) then pointed out the existence of histamine deamination and enzymes responsible for that reaction, and proposed monoamine oxidase as the name for the class of enzymes responsible for the oxidative deamination of the monoamines, and diamine oxidase for histaminase. The presence of monoamine oxidase in brain was first demonstrated by Pugh & Quastel in 1937. As the catecholamines became increasingly important, with the recognition of chemical nervous transmission and the growth of evidence that noradrenaline was the transmitter at peripheral adrenergic endings, attention focused on M A 0 as the counterpart of acetylcholinesterase for the sympathetic nervous system. This was rather controversial; there were many biochemical reasons why it did not seem to be likely. In 1957 Axelrod described catechol 0-methyltransferase, and later the reuptake of noradrenaline by the presynaptic ending, as the main mechanisms for the synaptic inactivation of catecholamines. (See Axelrod 1959.) The relationship of monoamine oxidase to psychiatry is an interesting historical development. Iproniazid was being used successfully in the treatment of tuberculosis in the fifties, but it had one serious disadvantage. In some patients it produced an undesirable behavioural activation. One of the early papers reporting the use of this substance in the treatment of tuberculosis in a sanatorium described the patients 'dancing in the halls'-and it wasn't because they had seen their X-ray pictures! It was soon realized that iproniazid was a nervous system activator of some kind. In 1955 Zeller et al. showed it to be a monoamine oxidase inhibitor and the idea came, first, I believe, to George Crane (1956) , that the undesirable side-effect in the treatment of tuberculosis might be a beneficial effect in the treatment of depression. Early trials supported this idea and several other monoamine oxidase inhibitors, less toxic than iproniazid, were then developed, by several pharmaceutical houses, with the knowledge that the inhibition of monoamine oxidase was the prerequisite for that activity. We shall have some discussion at this symposium on the therapeutic effectiveness of monoamine oxidase inhibitors in depression and their comparison with other antidepressant drugs.
The amount of monoamine oxidase in platelets was found by Murphy & Wyatt (1972) to be reduced in patients with schizophrenia. This was the first definitive biochemical finding in schizophrenia-made by competent scientists and with a unique control of schizophrenia-associated artifacts. It has been followed by a number of confirmatory reports, but also two which failed to find a difference. In the course of this symposium we shall have an opportunity to discuss that controversy and perhaps find some explanation of the lack of ability to confirm this result by some workers, and to decide whether this is an artifact or really characteristic of some forms of schizophrenia.
The history of monoamine oxidase and its implications in psychiatry and the reason why there is now a Ciba Foundation symposium on this topic is of interest in more than one way. I think it provides a salutary description of how scientific discoveries are made and how one moves from the accumulation of fundamental knowledge to knowledge of immediate social value. It may also have a sobering effect on the current tendencies to target research. One wonders whether any committee charged with programming research on mental illness would have supported Miss Hare in her studies of an enzyme in the liver, the implications of which for the nervous system were obscure. Apart from the interesting observations of Ewins & Laidlaw that the sympathetic innervation of muscle seemed to have something to do with this oxidase activity, one could not have imagined that the enzyme would have had important implications for the nervous system. Miss Hare in the discussion in her 1928 paper on the characteristics of the enzyme commented on its possible physiological role; she suspected that its important function was to detoxify tyramine and other amines coming into the body from bacterial putrefaction in the gut, by way of the liver. Even she did not foresee implications for behaviour and for psychiatric therapy. It was not until the serendipitous discovery of the behavioural activation produced by monoamine oxidase inhibitors as a side-effect in the treatment of tuberculosis that a committee concerned with its relevance to psychiatry could have taken up the matter. And, by that time, there were enough interested scientists able to recognize the implications for the nervous system and for psychiatry to take it up without the necessity of directing their efforts. In any case, our conference will recapitulate that history, in more modem terms; it is going to consider some of the biochemical aspects of the subject, then the pharmacological aspects, and finally the psychiatric implications of this interesting enzyme and its inhibitors. The apparent multiplicity of monoamine oxidase preparations from several sources may be abolished by treatment of soluble preparations with chaotropic agents such as sodium perchlorate. This treatment, which causes no loss of enzyme activity, results in the release of lipid material from the enzyme. Abolition of the multiple forms may also be effected by elution of the enzyme from DEAE-cellulose with the detergent Triton X-100, although in this case there is some loss of activity. Solubilization of the enzyme by prolonged sonication and detergent treatment causes a decrease in its sensitivity to selective inhibitors and a change in the kinetic reaction mechanism obeyed. Treatment of rat liver mitochondrial outer membranes with a chaotropic agent under mild conditions liberates a soluble form of the enzyme that is similar to the membrane-bound enzyme in its sensitivity to selective inhibitors and more vigorous treatment of this preparation with the chaotropic agent results in the loss of multiple forms without loss in activity. The use of the selective inhibitors clorgyline and deprenyl indicates that the majority of organs in the rat contain two enzyme species but some rat organs, such as spleen and testis, contain predominantly only a single species of the A type. The substrate specificities of the two species from rat liver are delineated.
The concept of a multiplicity of monoamine oxidases arose from studies of the temperature stabilities and inhibitor sensitivities of the activities of monoamine oxidase (amine: oxygen oxidoreductase [deaminating] [flavin-containing]; EC 1.4.3.4) towards different amine substrates (see Squires 1968; and Youdim 1973 for reviews). Use of the selective inhibitor clorgyline enabled Johnston (1968) to classify two major types of activity in mitochondria1 preparations from a number of sources. These two species were designated the A and B fractions, the former being active towards 5-hydroxytryptamine and tyramine and being more sensitive to inhibition by clorgyline than the B fraction, which was active towards benzylamine and tyramine. Subsequent work with this and other selective inhibitors confirmed this work and indicated that the two forms of monoamine oxidase could be detected in mitochondria from many, but by no means all, sources and that the relative proportions of these two forms varied widely between different organs and species (see e.g. Squires 1972; Knoll & Magyar 1972; Neff & Goridis 1972) .
The use of polyacrylamide gel electrophoresis (Collins et al. 1968 ) and cellulose acetate electrophoresis (Kim & D'Iorio 1968) considerably complicated this situation in that up to five bands of monoamine oxidase activity could be separated when partly purified soluble preparations of the enzyme were treated in this way. In addition the properties of the separated forms did not correspond to those detected in intact mitochondria from the same sources. Thus differences in the sensitivities of the forms separated from rat brain mitochondria to a number of selective inhibitors were not nearly great enough to account for the differences observed with mitochondrial preparations from this source (Youdim ef al. 1969; Squires 1972; Collins et al. 1972) . Such anomalies led us to suggest that the procedures used in making soluble preparations of the enzyme might affect the properties and the apparent multiplicity of the enzyme (see e.g. Tipton 1972 ).
THE NATURE OF THE MULTIPLE FORMS
In the cell monoamine oxidase is tightly bound to the mitochondria1 outer membrane and the techniques necessary to solubilize it for electrophoretic examination have usually involved prolonged sonication and treatment with a detergent. The possibility that those rather vigorous processes could lead to the formation of artifactually modified forms of the enzyme, by causing a single enzyme species to be released with varying amounts or types of membrane material bound to it, received support from our observation that the forms that could be separated by electrophoresis of soluble preparations of rat liver monoamine oxidase had widely different phospholipid contents (Tipton 1972 ; Houslay & Tipton 1973a) . Further evidence in favour of this idea came from the results of experiments in which solubilized preparations of the enzyme were treated with chaotropic agents such as sodium perchlorate or sodium thiocyanate. When monoamine oxidase obtained from rat liver (Houslay & Tipton 1973~) or human brain (Tipton ef al. 1973 ) was treated with a chaotropic agent under controlled conditions a considerable amount of lipid material, which could be separated by gel filtration, was liberated from the preparation and the resultant material migrated as a single band of activity on polyacrylamide gel electrophoresis. In addition the material treated in this way, which had lost no activity, did not respond in a biphasic manner to selective inhibitors and showed no differential loss of activity towards different substrates when subjected to thermal denaturation.
The apparent multiplicity of rat liver mitochondrial monoamine oxidase can also be abolished by eluting the enzyme from DEAE-cellulose with the nonionic detergent Triton X-100 (Houslay & Tipton 1975~) . A partly purified preparation of rat liver mitochondrial monoamine oxidase may be absorbed on to DEAE-cellulose in 20 mw-phosphate buffer at pH 7.4 and inclusion of 0.07576 Triton in the buffer causes the enzyme to be eluted as a sharp peak with the detergent front. The enzyme treated in this way migrates as a single band of activity on polyacrylamide gel electrophoresis and, whereas the enzyme applied to the DEAE-cellulose showed a selective response to the inhibitors clorgyline and deprenyl, the eluted material showed no such effect, as shown in Fig. 1 . This effect is particularly interesting since it had been previously shown that electrophoresis of a partly purified preparation of the enzyme in the presence of Triton resulted in the abolition of the multiple forms of the enzyme (Tipton 1972) . Further purification of the enzyme that had been eluted with Triton resulted in an enzyme preparation which appeared to be a homogeneous protein by the criterion of polyacrylamide gel electrophoresis.
These results strongly imply that the electrophoretically separable multiple forms of the enzyme result from the binding of lipid material and that treat- ment with chaotropic reagents or elution from DEAE-cellulose with Triton causes release of bound lipid material and abolition of the multiple forms. Indeed the phospholipid associated with the single band of activity in monoamine oxidase preparations that had been treated in this way was considerably reduced. It is tempting to conclude that the vigorous procedures used in 'solubilizing' the enzyme do indeed result in the generation of these forms, although the fact that an enzyme preparation that is sufficiently negatively charged to bind to DEAE-cellulose at pH 7.2 nevertheless contains a component that is positively charged at pH 9.2 would argue that the electrophoretic procedure itself may generate some of the bands of activity. Indeed one of the forms has been shown to be an artifact of the loading procedure used in the electrophoresis experiments (Houslay & Tipton 1973~) . The relevance of these results to the situation within the cell is not so clear, since the soluble preparation constitutes only about half the activity that was originally present in the mitochondria and, although the response of such preparations to selective inhibitors is broadly similar to the response of membrane-bound preparations of the enzyme, the soluble enzyme is considerably less sensitive to such inhibitors, as shown in Fig. 2 . This shows a comparison of the effects of clorgyline on the activity of rat liver monoamine oxidase in a preparation of mitochondrial outer membranes and in a preparation that had been rendered soluble by sonication and treatment with Triton X-100. It is clear that the solubilization procedure has rendered both components less sensitive to the inhibitor and has also decreased the difference between the two activities in terms of inhibitor sensitivity. This effect may be due to the vigorous procedures used in rendering the enzyme soluble causing a conformational change, to a conformational change occurring when the enzyme is released from a non-polar environment to one that is more polar, or simply to partitioning of the relatively lipophilic inhibitor between the aqueous phase and the less polar environment of the outer membrane.
Removal of the enzyme from mitochondrial outer membranes also causes a small but significant alteration in the kinetic mechanism obeyed by the enzyme (Houslay & Tipton 19736, 1975~) . The soluble and membrane-bound preparations obey broadly similar kinetic mechanisms but the kinetic data obtained with the former preparation are best interpreted in terms of a compulsory isomerization step in the reduced enzyme-ammonia complex before it can bind oxygen. A comparison between the kinetic mechanisms obeyed by the two preparations is shown in Fig. 3 . It is suggested that this conformational change, which does not appear to occur with the membrane-bound preparation, allows the soluble enzyme to adopt a conformation that is similar to that existing in the membrane-bound form, which is constrained in the 'E' conformation throughout the catalytic cycle. A related difference between the soluble and membrane-bound preparations is that the former is less sensitive to inhibition by the products ammonia and benzaldehyde when Ki values are determined with respect to the amine substrate (Houslay & Tipton 1975a) . This decreased sensitivity is also shown by the perchlorate-treated soluble enzyme. This effect may result from the different conformations of the two enzyme species (see Fig. 3) , since in the soluble preparation these products will inhibit by binding to the free enzyme species 'E" whereas in the membranebound preparation they will interact with 'E'.
Whatever their causes, these changes that accompany solubilization of the enzyme have led us to conclude that work with preparations of the enzyme that had been rendered soluble by the vigorous procedures frequently used (and with the multiple forms that may be separated from them) cannot be expected to provide useful information on the nature and control of the monoamine oxidase activities within the cell.
In an investigation of milder procedures for obtaining soluble preparations of the enzyme we have found that treatment of preparations of rat liver mitochondria1 outer membranes with a chaotropic agent under mild conditions followed by gel filtration in the presence of Triton X-100 results in the release of enzyme from membranes. This soluble form of the enzyme can be obtained in very high yields ( -907; of that originally present in the outer membranes), and it behaves in a very similar way to the membrane-bound enzyme in its response to selective inhibitors such as deprenyl (Fig. 4) . More vigorous treatment with a chaotropic agent in the manner previously described (Houslay & Tipton 1973a ) could be used to convert this material into a preparation that showed no indication of multiplicity in its response to selective inhibitors without loss of activity. These enzyme preparations are compared in Fig. 4 . Clearly it is possible to convert the membrane-bound enzyme into a soluble form that still retains the inhibitor sensitivity associated with the starting material. This result may suggest that the decreased inhibitor sensitivity in preparations that have been rendered soluble by sonication and detergent treatment is due to these procedures damaging the enzyme, although the possibility that the difference may result from different amounts or types of lipid material being bound to the two soluble preparations cannot be excluded.
The observation that the membrane-bound enzyme could be converted into a species that appeared to be homogeneous, in terms of monoamine oxidase activity, without loss of enzyme activity would suggest that, like the soluble enzyme, the multiple forms of the membrane-bound enzyme result from the action of environmental factors on a single enzyme species. The conclusion that there is only a single species of monoamine oxidase in a given organ and that its activity may be modified by binding to membrane material indicates that any changes in the specificities of the enzyme that accompany changes in mental state should best be interpreted in terms of changes in the environment of the enzyme rather than in the enzyme protein itself.
MULTIPLICITY IN MEMBRANE-BOUND PREPARATIONS
The use of selective inhibitors has provided useful information on the situation that is likely to exist within the cell, and there is a considerable body of evidence to indicate that there are two major species of enzyme activity in mitochondria from a number of sources (see e.g. Squires 1972; Neff et ul. 1973; Mantle et al. 1975) . The proportions of these two forms have been found to vary widely between different organs and in some organs it has been found that there is essentially only one species present. In order to build up a picture of the situation in a single animal species we have investigated the occurrence of the major forms in a number of organs from the rat. These results extend those of previous workers, whose data are included with our own in Table 1 . The proportions of the two forms do indeed appear to vary widely and some organs, including the spleen, seem to be largely composed of the A species. Since the spleen shares an embryological origin with a component of the nonparenchymal cells of liver it was of interest to see if the parenchymal cells contributed one form to the duality of monoamine oxidase in liver, whereas the other form was contributed by the non-parenchymal cells. Parenchymal cells from rat liver were prepared by the method of Howard & Pesch (1968) . The table shows that the parenchymal cells closely resemble whole liver in their content of the two forms.
Since there is an adrenergic innervation in the non-parenchymal cells of rat liver (Ungvriry & Donrith 1969), it was of interest to investigate the effect of adrenergic denervation on the activities of the two species. This was attempted by treating male rats with 6-hydroxydopamine (injections of 30 mg/kg on day 1, day 2 and day 8 before killing on day 9). Rats treated in this way showed typical features of chemical sympathectomy in that electron microscopy revealed an absence of nerve terminals in the heart and noradrenaline in the heart was depleted. This treatment, however, resulted in no significant change in the specific activity of the liver monoamine oxidase towards tyramine as compared with controls (rats injected with saline instead of 6-hydroxydopa-mine) and the ratio of the enzyme species determined using clorgyline was unchanged (M. D. Houslay & G. Lyles, unpublished observations). This evidence, together with the results obtained with separated parenchymal cells, suggests that these two enzyme species may exist in similar proportions in all major cell types in rat liver. Such a distribution would be in agreement with the results of Jarrott (197 1) who demonstrated in denervation experiments that both species existed in neuronal and extraneuronal cells of rat vas deferens, and with those of who reached similar conclusions in the case of rat mesenteric arterial monoamine oxidase, although in this case the A species appeared to predominate in the neuronal cells. However, the amount of activity associated with the adrenergic innervation may be too small to be significant.
It is interesting that testis contains predominantly the A species of monoamine oxidase activity, since it has been reported that spermatogenesis and testicular weight are adversely affected by administered 5-hydroxytryptamine (see e.g. Salgado & Green 1955; Boccabella et al. 1962; O'Steen 1963) , which is a substrate for this form of the enzyme.
In an attempt to see if enzyme activities of predominantly the A type responded to chaotropic agents in the same way as the A/B mixtures previously used, a soluble preparation of monoamine oxidase was made from rat spleen mitochondria in the way previously described for rat liver monoamine oxidase (Houslay & Tipton 1973~) . This soluble preparation resembled the membranebound material in spleen in being predominantly (greater than 95%) of the A type. Preliminary experiments indicated that treatment of this material with perchlorate under the conditions previously described (Houslay & Tipton 1973a ) resulted in its conversion to a form that was similar to the perchloratetreated enzymes from liver and brain in bearing a closer resemblance to the B species in terms of its inhibitor sensitivity.
THE SPECIFICITIES OF THE MULTIPLE ACTIVITIES IN RAT LIVER
We have made a detailed study of the specificities of the two major forms of activity in rat liver mitochondria1 outer membranes using the inhibition of the enzyme by clorgyline to assess whether a given amine was a substrate for both activities or for only one. The results obtained in this way were validated by use of the reversible inhibitors benzyl cyanide and Ccyanophenol. These compounds act as competitive inhibitors of the B enzyme and mixed inhibitors of the A enzyme, whereas with respect to amines that are substrates for both enzyme activities, inhibition plots are non-linear . The specificities worked out in these ways, which are shown in Table 2, confirm TABLE 2 The specificities of monoamine oxidase species in rat liver mitochondria1 outer membranes
Substrate
Oxidized and extend those of previous workers (Johnston 1968; Hall et al. 1969; Neff et al. 1973; Neff & Goridis 1972) . Since the multiple activities of monoamine oxidase preparations result from a single enzyme species being bound in different lipid environments, it follows that different lipid compositions of mitochondria from different species and organs could result in the specificities of the major forms differing from source to source and thus the results obtained with other systems may differ from those reported here for rat liver. An interesting observation that has been made by a number of workers is that the method of mixed substrates (Dixon & Webb 1964) , which should provide a sensitive indication of the presence of more than one enzyme species, fails to provide any indication of multiplicity in the case of monoamine oxidase. We have shown that this paradox may be resolved by the assumption that any substrate will bind to both forms of the enzyme with similar affinity constants but that in most cases it will act as a substrate for one species and an inhibitor of the other ). This conclusion, that substrates for one species will act as inhibitors of the other, imposes certain restrictions on the likely effects of selective inhibition of one species (Houslay & Tipton 19756) . Thus one would expect a 'damping out' of the specific effects of selective inhibitors in vivo, since inhibition of one species of the enzyme would be expected to cause an elevation of the levels of the substrates for that species and thus result in reversible inhibition of the other species. 
Discussion
Oreland: Dr Ekstedt and I have done experiments on rat liver monoamine oxidase rather similar to yours, Dr Tipton, but with somewhat different results (Ekstedt & Oreland 1975) . We delipidated the mitochondrial membranes by extraction with aqueous methyl ethyl ketone. Originally this was a two-step procedure (Hollunger & Oreland 1970) , rendering the enzyme soluble, but by using only the first step we obtained delipidated membranes with the enzyme still bound, which then served as the material for our studies. This bound, delipidated form of the enzyme, however, seems to be very similar to the soluble form (B. Ekstedt & L. Oreland, unpublished work). After delipidation with the ketone extraction procedure we recovered the B form activity of the enzyme completely, but almost nothing of the A form. We have shown that there is no transformation from the A form to the B form during the extraction procedure, but that the A form is probably inactivated.
Our results suggest that if there are two forms of the enzyme, and not just two areas of the active site, as proposed by Severina (1973), it seems likely that
